Your browser is no longer supported. Please, upgrade your browser.
Settings
ARQL ArQule, Inc. daily Stock Chart
ARQL [NASD]
ArQule, Inc.
Index- P/E- EPS (ttm)-0.33 Insider Own0.60% Shs Outstand71.15M Perf Week-3.28%
Market Cap83.96M Forward P/E- EPS next Y-0.37 Insider Trans0.00% Shs Float62.91M Perf Month-8.53%
Income-22.70M PEG- EPS next Q-0.11 Inst Own60.40% Short Float0.94% Perf Quarter-7.09%
Sales4.70M P/S17.86 EPS this Y-48.60% Inst Trans2.05% Short Ratio2.89 Perf Half Y-26.25%
Book/sh0.33 P/B3.58 EPS next Y9.80% ROA-55.40% Target Price3.35 Perf Year-31.79%
Cash/sh0.44 P/C2.69 EPS next 5Y5.00% ROE-70.20% 52W Range1.13 - 2.17 Perf YTD-6.35%
Dividend- P/FCF- EPS past 5Y-9.80% ROI-96.60% 52W High-45.62% Beta1.47
Dividend %- Quick Ratio3.70 Sales past 5Y-37.00% Gross Margin- 52W Low4.42% ATR0.06
Employees36 Current Ratio3.70 Sales Q/Q-57.10% Oper. Margin- RSI (14)33.31 Volatility2.36% 4.63%
OptionableYes Debt/Eq0.00 EPS Q/Q-111.70% Profit Margin- Rel Volume0.41 Prev Close1.18
ShortableYes LT Debt/Eq0.00 EarningsMar 07 BMO Payout- Avg Volume205.54K Price1.18
Recom2.50 SMA20-5.14% SMA50-14.11% SMA200-20.73% Volume84,647 Change0.00%
Dec-21-15Upgrade RBC Capital Mkts Sector Perform → Outperform $4 → $5
Dec-09-15Resumed Leerink Partners Mkt Perform
May-12-14Reiterated MLV & Co Hold $3 → $1.75
May-24-13Reiterated MLV & Co Hold $2.25 → $3
Jan-14-13Downgrade MLV & Co Buy → Hold $4 → $2.25
Oct-02-12Downgrade Needham Buy → Hold
Sep-12-12Initiated Burrill Institutional Research Mkt Outperform $10
Jul-30-12Initiated Needham Buy
Mar-15-12Initiated Stifel Nicolaus Buy $13
Jan-31-12Initiated RBC Capital Mkts Outperform $11
May-26-11Initiated Global Hunter Securities Accumulate $11
Apr-01-10Reiterated Mehta Partners Outperform $5 → $9
Oct-13-09Upgrade UBS Sell → Buy
Jul-16-09Downgrade UBS Neutral → Sell
Jun-10-09Reiterated Lazard Capital Mkts Buy $5 → $7
Apr-03-09Downgrade UBS Buy → Neutral
Dec-12-08Initiated UBS Buy
Dec-01-08Reiterated Oppenheimer Outperform $7 → $6
Sep-03-08Upgrade Banc of America Sec Neutral → Buy $6 → $7
Aug-13-08Reiterated Cantor Fitzgerald Buy $9 → $7.50
Mar-21-17 11:28AM  ArQule, Inc. :ARQL-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
Mar-15-17 01:04PM  ARQULE INC Financials
Mar-14-17 02:48PM  ArQule, Inc. :ARQL-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
Mar-09-17 04:43PM  ARQULE INC Files SEC form 10-K, Annual Report
Mar-07-17 04:02PM  Edited Transcript of ARQL earnings conference call or presentation 7-Mar-17 2:00pm GMT
07:31AM  ARQULE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:12AM  ArQule reports 4Q loss
07:07AM  Q4 2016 ArQule Inc Earnings Release - Before Market Open
07:00AM  ArQule Reports Fourth Quarter and Full Year 2016 Financial Results Business Wire
Feb-24-17 07:00AM  ArQule To Report Fourth Quarter and Year End 2016 Financial Results On March 7, 2017 Business Wire
Feb-20-17 12:30PM  ArQule Liver Cancer Drug Fails Phase 3 Trial at Investopedia
11:07AM  ArQule, Inc. (ARQL)s Liver Cancer Drug Fails: Whats Next? at Insider Monkey
Feb-17-17 04:04PM  Sabre Corp., L Brands Dip into Fridays 52-Week Low Club -18.37%
07:31AM  ARQULE INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
06:00AM  Daiichi Sankyo and ArQule Announce the Completion of the METIV-HCC Phase 3 Study of Tivantinib in Second-Line Treatment of MET-Overexpressing Hepatocellular Carcinoma Business Wire
Feb-08-17 07:00AM  ArQule to Present at The Leerink Partners 6th Annual Global Healthcare Conference on February 15, 2017 Business Wire
Jan-13-17 08:00AM  ArQule (ARQL) Catches Eye: Stock Moves 7.2% Higher +6.04%
Jan-10-17 07:31AM  ARQULE INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation +5.30%
Dec-21-16 11:58AM  ETFs with exposure to ArQule, Inc. : December 21, 2016
Dec-20-16 02:02PM  How ArQule, Inc. (ARQL) Stacks Up Against Its Peers at Insider Monkey
Dec-04-16 09:00PM  Data on Proprietary BTK Inhibitor, ARQ 531, Demonstrating Inhibition of Wild Type and C481S Mutant BTK and Superiority to Ibrutinib in TCL1 Mouse Model Presented at the American Society of Hematology Annual Meeting Business Wire
Dec-03-16 05:45PM  Preclinical Data on Proprietary AKT Inhibitor, ARQ 092, Demonstrating Effectiveness in the Treatment of Sickle Cell Disease Presented at the American Society of Hematology Annual Meeting Business Wire
Nov-10-16 04:01PM  Could Trump Tax Cut Plans, Republican Congress Spur Biotech M&A?
Nov-08-16 11:00AM  ArQule, Inc. :ARQL-US: Earnings Analysis: Q3, 2016 By the Numbers : November 8, 2016
Nov-07-16 12:48PM  Edited Transcript of ARQL earnings conference call or presentation 7-Nov-16 2:00pm GMT
08:01AM  ARQULE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:07AM  Q3 2016 ArQule Inc Earnings Release - Before Market Open
07:04AM  ArQule reports 3Q loss
07:00AM  ArQule Reports Third Quarter 2016 Financial Results Business Wire
Nov-03-16 09:05AM  Advancements in ArQules Proprietary Pipeline to be Highlighted at the 2016 American Society of Hematology Annual Meeting Business Wire
Oct-26-16 06:04AM  ARQULE INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Oct-24-16 07:00AM  ArQule To Report Third Quarter 2016 Financial Results On November 7, 2016 Business Wire
Sep-28-16 11:03AM  Can The Uptrend Continue for ArQule (ARQL)?
Sep-21-16 07:00AM  ArQule to Present at The Leerink Partners Rare Disease and Immuno-Oncology Roundtable on September 28, 2016 Business Wire
Sep-19-16 09:44AM  ETFs with exposure to ArQule, Inc. : September 19, 2016 +8.63%
Sep-15-16 07:00AM  ArQule Announces Publication of Manuscript Highlighting Preclinical Activity of FGFR Inhibitor, ARQ 087, in Peer Reviewed Journal Business Wire
Sep-08-16 10:06AM  ETFs with exposure to ArQule, Inc. : September 8, 2016
Aug-25-16 10:01AM  ETFs with exposure to ArQule, Inc. : August 25, 2016
Aug-11-16 12:30PM  ETFs with exposure to ArQule, Inc. : August 11, 2016
Aug-05-16 12:24PM  ArQule, Inc. :ARQL-US: Earnings Analysis: Q2, 2016 By the Numbers : August 5, 2016
Aug-03-16 04:43PM  Edited Transcript of ARQL earnings conference call or presentation 3-Aug-16 1:00pm GMT
07:31AM  ARQULE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:08AM  ArQule reports 2Q loss
07:07AM  Q2 2016 ArQule Inc Earnings Release - Before Market Open
07:00AM  ArQule Reports Second Quarter 2016 Financial Results Business Wire
Jul-20-16 07:00AM  ArQule To Report Second Quarter 2016 Financial Results On August 3, 2016 GlobeNewswire
Jul-18-16 04:00PM  ArQule Presents Preclinical Data for ARQ 531, a Proprietary Reversible Inhibitor of Wild Type and Mutant BTK, at the 2016 Pan Pacific Lymphoma Conference GlobeNewswire
Jul-05-16 07:00AM  ArQule to Present at Cantor Fitzgeralds 2nd Annual Healthcare Conference on July 12, 2016 GlobeNewswire -5.41%
Jul-01-16 12:36PM  Heres What The ArQule, Inc. (ARQL) Data Really Means at Insider Monkey
Jun-30-16 07:00AM  ArQule Presents Preliminary Clinical Data for ARQ 087 Demonstrating Evidence of Anticancer Activity in Intrahepatic Cholangiocarcinoma at the ESMO 18th World Congress on Gastrointestinal Cancer GlobeNewswire
Jun-28-16 03:52PM  Forget Valeant, Invest in These Attractive Drug Stocks Instead
Jun-23-16 08:25AM  ArQule (ARQL) Shows Strength: Stock Adds 8% in Session
07:00AM  ArQule to Present Preliminary Phase 1/2 Data for FGFR Inhibitor, ARQ 087, in Intrahepatic Cholangiocarcinoma at the ESMO 18th World Congress on Gastrointestinal Cancer GlobeNewswire
Jun-20-16 02:02PM  ETFs with exposure to ArQule, Inc. : June 20, 2016
05:00AM  ArQule: Advancing a Deep and Diverse Clinical Stage Pipeline Accesswire
Jun-08-16 11:24AM  Valeant (VRX) Stock Down on Bleak View, Q1 Earnings Miss
May-26-16 12:12PM  ARQULE INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
May-17-16 01:56PM  ArQule, Inc. :ARQL-US: Earnings Analysis: Q1, 2016 By the Numbers
May-11-16 09:01AM  Repros (RPRX) Q1 Loss Narrower Y/Y, Pipeline in Focus Zacks
May-04-16 06:40PM  Edited Transcript of ARQL earnings conference call or presentation 4-May-16 1:00pm GMT
08:01AM  ARQULE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:20AM  ArQule reports 1Q loss
07:07AM  Q1 2016 ArQule Inc Earnings Release - Before Market Open
07:00AM  ArQule Reports First Quarter 2016 Financial Results GlobeNewswire
Apr-20-16 07:30AM  ArQule To Report First Quarter 2016 Financial Results On May 4, 2016 GlobeNewswire +7.06%
Apr-14-16 04:32PM  ARQULE INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits +6.49%
Apr-13-16 11:50AM  Valeant (VRX) Receives Notice of Default: Stock in Trouble?
Apr-08-16 03:35PM  Intercept's (ICPT) Ocaliva Gets Favorable FDA Panel Vote +6.25%
Apr-06-16 11:10AM  Intercept (ICPT) Up Ahead of Advisory Committee Meeting
10:30AM  Valeant Completes Accounting Review of Philidor, Shares Up
Apr-05-16 07:30AM  ArQule to Present at the 15th Annual Needham Healthcare Conference on April 12, 2016 GlobeNewswire
Mar-30-16 04:45PM  Shire (SHPG) Wins Lialda Patent Trial vs. Allergan
Mar-29-16 04:45PM  Valeant CEO Gets Subpoena from Senate Aging Committee
Mar-28-16 09:36AM  ETFs with exposure to ArQule, Inc. : March 28, 2016
Mar-24-16 09:30AM  Roche Files for FDA Approval of Elecsys BRAHMS Assay
Mar-22-16 05:03PM  ARQULE INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits +13.07%
12:40PM  Valeant to Get a New CEO Amid Turmoil, Ackman on Board
07:30AM  Daiichi Sankyo and ArQule Announce Continuation of METIV-HCC Phase 3 Study of Tivantinib in Second-Line Hepatocellular Carcinoma GlobeNewswire
Mar-21-16 05:28PM  McKesson (MCK) to Restructure Operations, Lower Headcount
Mar-18-16 01:30PM  Pfizer Inc (PFE) Reports 4.4% Position in Arqule Inc (ARQL) at Insider Monkey
Mar-14-16 04:04PM  ETFs with exposure to ArQule, Inc. : March 14, 2016
10:39AM  ArQule, Inc. :ARQL-US: Earnings Analysis: Q4, 2015 By the Numbers
Mar-10-16 05:09PM  Valeant Terminates Litigation with R&O Pharmacy
Mar-09-16 10:42AM  Sucampo Beats Earnings & Revenues on Strong Amitiza Sales
Mar-04-16 08:31AM  ARQULE INC Files SEC form 8-K/A, Other Events
Feb-29-16 01:05PM  Edited Transcript of ARQL earnings conference call or presentation 29-Feb-16 2:00pm GMT
09:00AM  ArQule Inc Earnings Call scheduled for 9:00 am ET today
08:27AM  ARQULE INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
07:37AM  ArQule reports 4Q loss
07:07AM  Q4 2015 ArQule Inc Earnings Release - Before Market Open
07:00AM  ArQule Reports Fourth Quarter and Full Year 2015 Financial Results GlobeNewswire
06:55AM  ArQule Announces $15.3 Million Registered Direct Offering of Common Stock GlobeNewswire
Feb-19-16 08:15AM  ArQule (ARQL) Shows Strength: Stock Adds 7.6% in Session
Feb-15-16 07:30AM  ArQule to Report Fourth Quarter and Full Year 2015 Financial Results on February 29, 2016 GlobeNewswire
Feb-04-16 07:30AM  ArQule to Present at Upcoming Investor Conferences GlobeNewswire
Jan-28-16 07:30AM  ArQule Provides Proprietary Pipeline Update for AKT Inhibitors GlobeNewswire
Jan-25-16 07:30AM  ArQule Presents Clinical Biomarker Data From Phase 2 Study and Ongoing Phase 3 METIV-HCC Study of Tivantinib in Second-Line Hepatocellular Carcinoma at the 2016 Gastrointestinal Cancers Symposium GlobeNewswire
Jan-08-16 12:13PM  12 Biotechs With Binary Events Coming This Year
Dec-24-15 10:36AM  ArQule, Inc. Earnings Analysis: Q3, 2015 By the Numbers
Dec-21-15 06:12AM  ArQule upgraded by RBC Capital Mkts +6.34%
ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. Its lead product candidate is tivantinib (ARQ 197), a small molecule inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase III clinical trial for the treatment of liver cancer and non-small cell lung cancer; Phase II clinical trial for the treatment of mesothelioma and kidney cancer; and Phase I clinical trial for the treatment of pediatric tumors, as well as has completed Phase II clinical trial for the treatment of colorectal cancer. The company's early clinical-stage products include ARQ 092, an inhibitor of the AKT serine/threonine kinase in Phase Ib clinical trials; ARQ 087, a multi-kinase inhibitor of the fibroblast growth factor receptor (FGFR) family Phase II clinical trial for patients with intrahepatic cholangiocarcinoma and FGFR translocations, amplification, and mutations; and ARQ 761, an intravenously administered analogue of Beta-lapachone, which is Phase 1b clinical trial used as a promoter of NQo1-mediated programmed cancer cell necrosis. Its pre-clinical development program also includes ARQ 751, a next-generation inhibitor of AKT. The company has co-development and co-commercialization agreement with Daiichi Sankyo Co., Ltd.; license agreement with Kyowa Hakko Kirin Co., Ltd.; collaborative research and development agreement with Beryllium Development Corp.; and collaboration agreement with the National Human Genome Research Institute of the NIH. Arqule, Inc. was founded in 1993 and is headquartered in Burlington, Massachusetts.